Since Ma-Mel-63a cells that were long-term exposed to BRAFi and MEKi (Ma-Mel-63a dr) turned out to be still sensitive to BRAF and MEK inhibition (Supplementary Figure 15), we induced BRAFi- and MEKi resistance in the BRAFV600-mutated melanoma cell line SK-Mel-28 by long-term exposition to vemurafenib and cobimetinib. The gene discussed is BRAF; the disease is melanoma.